FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Price & Overview
NASDAQ:FBIOP • US34960Q2084
Current stock price
The current stock price of FBIOP is 13.585 USD. Today FBIOP is up by 0.26%. In the past month the price decreased by -3.52%. In the past year, price increased by 137.09%.
FBIOP Key Statistics
- Market Cap
- 421.678M
- P/E
- N/A
- Fwd P/E
- 1,331.86
- EPS (TTM)
- -0.88
- Dividend Yield
- N/A
FBIOP Stock Performance
FBIOP Stock Chart
FBIOP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FBIOP. When comparing the yearly performance of all stocks, FBIOP is one of the better performing stocks in the market, outperforming 94.57% of all stocks.
FBIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FBIOP. Both the profitability and financial health of FBIOP have multiple concerns.
FBIOP Earnings
On March 31, 2026 FBIOP reported an EPS of -0.01 and a revenue of 16.08M. The company missed EPS expectations (-108.91% surprise) and missed revenue expectations (-39.76% surprise).
FBIOP Forecast & Estimates
8 analysts have analysed FBIOP and the average price target is 42.99 USD. This implies a price increase of 216.42% is expected in the next year compared to the current price of 13.585.
For the next year, analysts expect an EPS growth of 101.16% and a revenue growth 49.34% for FBIOP
FBIOP Groups
Sector & Classification
FBIOP Financial Highlights
Over the last trailing twelve months FBIOP reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 73.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.94% | ||
| ROE | -9.55% | ||
| Debt/Equity | 0.86 |
FBIOP Ownership
FBIOP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBIOP
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
IPO: 2011-11-17
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA US
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ
Can you describe the business of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
What is the current price of FBIOP stock?
The current stock price of FBIOP is 13.585 USD. The price increased by 0.26% in the last trading session.
Does FORTRESS BIOTECH INC - FBIO 9 3/8 PERP pay dividends?
FBIOP does not pay a dividend.
What is the ChartMill rating of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP stock?
FBIOP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for FBIOP stock?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) currently has 101 employees.
What is FORTRESS BIOTECH INC - FBIO 9 3/8 PERP worth?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a market capitalization of 421.68M USD. This makes FBIOP a Small Cap stock.
When does FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) report earnings?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) will report earnings on 2026-05-13.